Ann Dermatol.  2015 Dec;27(6):774-775. 10.5021/ad.2015.27.6.774.

The Clinical Efficacy of Azathioprine in Korean Patients with Atopic Dermatitis

• Lee H
• Shin JU
• Lee KH

• KMID: 2157462
• DOI: http://doi.org/10.5021/ad.2015.27.6.774

Abstract

No abstract available.

MeSH Terms

Azathioprine*
Dermatitis, Atopic*
Humans
Azathioprine

Figure

• 

  Fig. 1 Change in the eczema area and severity index (EASI) score before and after azathioprine treatment (mean treatment duration, 22.20±19.84 weeks). There was a 42% reduction in the EASI score from the baseline (p<0.017). *Statistically significant difference compared with the baseline.

• 

  Fig. 2 Changes in pruritus and loss of sleep (LOS) before and after azathioprine treatment (mean treatment duration, 22.20±19.84 weeks). On the visual analogue scale, the degree of pruritus decreased from 7.35±1.66 to 4.10±2.89 (p<0.001), and LOS decreased from 6.55±1.88 to 3.10±2.86 (p<0.001). *Statistically significant difference compared with the baseline.

Reference

1. Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol. 2013; 132:774.

2. Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008; 33:710–711.

3. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002; 147:324–330.

4. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006; 367:839–846.